Wegovy 0.25ml: what the starting injection volume actually tells you

Why does the 0.25ml figure appear, and what does it actually measure?

When people search for "Wegovy 0.25ml" they are usually looking at the pen's label or their patient leaflet and wondering whether the volume is something they need to track. It is not. The pre-filled Wegovy pen delivers a fixed 0.25ml injection each time you use it at the starting stage, that fluid contains 0.25mg of semaglutide dissolved in solution. The pen is factory-set; there is no syringe to fill, no dial to adjust for volume.

What changes as you move up the titration schedule is the concentration of semaglutide in that fluid, not the volume itself. So a higher-dose pen still delivers the same 0.25ml of liquid, but each millilitre contains more active medicine. This is a standard pharmaceutical design choice: keeping the injected volume constant makes the injection experience predictable at every stage, which matters when you are self-administering weekly at home.

A quick habit worth building early: before each injection, check the pen's label against your prescription summary to confirm the strength written there matches what your prescriber last approved. It takes under a minute and is especially useful if you have recently moved up a dose tier. The 0.25mg starting dose explained covers what to expect in those first weeks in more detail.

Is 0.25mg in 0.25ml a therapeutic dose, or is something else going on?

This is one of the most common questions our prescribers hear. The honest answer: the first pen's job is adjustment, not weight loss. Clinical trial data published in the STEP 1 trial in the New England Journal of Medicine showed an average body-weight reduction of around 15 per cent over 68 weeks at the 2.4mg maintenance dose, but participants spent only the first four weeks at 0.25mg before the prescriber moved them upward through the schedule.

The starting dose quietens the gastrointestinal effects that semaglutide can produce: nausea, loose stools, an unsettled stomach. Beginning lower gives the body time to adapt, which means fewer people stop treatment early because of side effects. It is a tolerability measure built into the licensed protocol, not a clinical threshold in its own right.

The NHS medicines page for semaglutide sets out the full titration pathway and what to expect at each stage, including guidance on when to contact your prescriber if side effects feel difficult to manage.

What happens after the 0.25mg/0.25ml phase, and who decides when to move on?

Your prescriber does, based on how your body has responded and what your treatment record shows. The licensed schedule moves from the 0.25mg pen, which is where every course begins, through 0.5mg, 1.0mg, 1.7mg and up to a 2.4mg maintenance dose, with roughly four weeks at each level. More recently, the MHRA approved a 7.2mg maximum dose for eligible adults; the dedicated 7.2mg single-dose pen was cleared on 14 April 2026, giving prescribers an additional option for people with obesity who need or tolerate a higher maintenance level.

None of this titration happens automatically. At nume, a GPhC-registered Independent Prescriber reviews your case before each repeat, your consultation does not pass through an automated system. If you are transferring from another provider or requesting a dose increase, clinical evidence of your current treatment is part of that review. It is worth reading about what results to realistically expect at the early dose stages, so that the first few weeks do not feel like the medicine is not working when in fact it is doing exactly what it was designed to do.

Wegovy is a prescription-only medicine. Adults with a BMI of 30 or above, or 27 or above alongside a weight-related health condition such as high blood pressure or type 2 diabetes, may be eligible, but BMI alone is not the whole picture. If you would like to understand where you stand, our weight loss treatment overview covers the licensed options and how eligibility works in practice. For a broader look at how Wegovy 0.25 fits into the treatment journey alongside other available medicines, the Wegovy overview is a good starting point.

When you are ready to talk it through with a prescriber, start your free consultation and a clinician will review your answers the same day.